reason report
updat jakafi miss inventori drawdown pipelin remain
track
bottom line report jakafi revenu
consensu sale impact inventori headwind
quarter pipelin remain track
snda ruxolitinib gvhd graft vs host diseas accept
prioriti review pdufa date set feb expect share
weaker follow below-consensu jakafi sale
absenc pipelin updat materi chang
invest thesi fundament continu see jakafi
franchis worth per share suggest minim valu
attribut pipelin note investor longer term
time horizon may becom construct share
jakafi revenu miss consensu inventori provid
jakafi revenu consensu
quarter includ price increas taken end august
off-set headwind relat inventori
draw manag comment suggest draw
revers octob compani narrow guidanc
rais lower end rang expect
jakafi revenu year midpoint suggest
yoy growth vs lower estim jakafi
slightli midpoint guidanc
iclusig sale jakavi olumi royalti mostli in-lin
report net revenu iclusig sale europ slightli
consensu estim royalti revenu quarter
includ jakavi ex-u sale relat eli
lilli sale olumi quarter also includ mileston
lilli relat initi phase program baricitinib
jakafi label expans feb provid updat
numer pipelin asset includ ruxolitinib itacitinib gvhd
compani supplement new drug applic snda ruxolitinib
gvhd base posit result trial recent
accept prioriti review fda assign pdufa date
februari commerci readi activ ahead potenti approv
commenc compani believ size structur
sale forc optim execut label expans
launch approv multipl gvhd data releas anticip
includ first phase data itacitinib treatment-na
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
compani inform leerink partner llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
acut gvhd trial well phase data ruxolitinib
steroid refractori acut chronic gvhd
trial continu see jak inhibit program gvhd
import expans opportun model total peak
sale program repres current
pivot clinic data pemigatinib baricitinib atop derm
also expect also provid updat late-
stage program includ pan-fgfr inhibitor pemigatinib
recent featur data present european societi
medic oncolog esmo congress see takeaway note
anticip submit nda pemigatinib base
data phase trial cholangiocarcinoma patient
harbor mutat data continu dose
cohort trial bladder cancer could potenti enabl
registr meaning larger opportun anticip
complet enrol continu dose cohort
compani also expect partner announc pivot phase
data baricitinib atop dermat includ
pemigatinib baricitinib olumi royalti atop dermat
model combin cholangiocarcinoma/bladd opportun
repres per share risk-adjust npv atop derm
catalyst includ updat decemb pdufa
gvhd februari multipl data present
american societi hematolog annual meet decemb
includ updat data jakafi combin compani
inhibitor treatment myelofibrosi
combin could play import role extend runway
jakafi franchis myeloprolif neoplasm mpn ip current
anticip run abstract expect
publish on-line novemb beyond see sever
catalyst includ potenti materi updat
competitor confer earli januari earn earli
februari februari pdufa date ruxolitinib gvhd
rate corp share market perform pt commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev follow recent disappoint relat compani lead pipelin asset
epacadostat see limit opportun transform catalyst next month
promis asset pipelin see anyth emerg
near term believ replac perceiv epacadostat commerci opportun
gener signific investor enthusiasm stock howev share could repres
good invest investor longer term horizon beyond one year valuat
will invest mid-cap biotechnolog compani solid financi fundament driven
grow commerci backbon anticip minim volatil
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl jak i/o pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jak i/o pipelin incyt corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
total incom expens
earn tax ebt
balanc sheet mn
compani report leerink partner estim
